Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.52) by 3.85 percent. This is a 28.21 percent decrease over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $14.74 million which missed the analyst consensus estimate of $18.12 million by 18.61 percent. This is a 9.30 percent increase over sales of $13.49 million the same period last year.
精彩评论